Vertex Pharmaceuticals (VRTX) Deferred Taxes (2011 - 2026)
Vertex Pharmaceuticals' quarterly Deferred Taxes came in at -$65.3 million in Q1 2026, up 65.92% year-on-year from -$39.4 million in Q1 2025, and down 314.1% quarter-over-quarter from $30.5 million in Q4 2025.
Vertex Pharmaceuticals has reported Deferred Taxes for 16 years, with the latest figure at -$65.3 million in Q1 2026.
- For the quarter ending Q1 2026, Deferred Taxes rose 65.92% year-over-year to -$65.3 million; the trailing twelve-month figure through Mar 2026 stood at -$384.5 million (down 0.63% YoY), and the FY2025 full-year result was -$510.8 million, down 46.44% from the prior year.
- Deferred Taxes for Q1 2026 stood at -$65.3 million, down from $30.5 million in the prior quarter.
- The five-year high for Deferred Taxes was $148.1 million in Q4 2022, with the low at -$235.9 million in Q3 2025.
- Average Deferred Taxes over 5 years is -$102.2 million, with a median of -$118.8 million recorded in 2024.
- Year-over-year, Deferred Taxes soared 453.46% in 2022 and sank 821.95% in 2023.
- Tracing VRTX's Deferred Taxes over 5 years: stood at $148.1 million in 2022, then tumbled by 188.45% to -$131.0 million in 2023, then surged by 139.39% to $51.6 million in 2024, then sank by 40.89% to $30.5 million in 2025, then sank by 314.1% to -$65.3 million in 2026.
- The last three Deferred Taxes figures came in at -$65.3 million (Q1 2026), $30.5 million (Q4 2025), and -$235.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -65.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 96.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 9.31 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.30 Mn |
| Dec 31, 2025 | 30.50 Mn |
| Sep 30, 2025 | -235.90 Mn |
| Jun 30, 2025 | -113.80 Mn |
| Mar 31, 2025 | -191.60 Mn |
| Dec 31, 2024 | 51.60 Mn |
| Sep 30, 2024 | -123.30 Mn |
| Jun 30, 2024 | -118.80 Mn |
| Mar 31, 2024 | -158.30 Mn |
| Dec 31, 2023 | -131.00 Mn |
| Sep 30, 2023 | -115.50 Mn |
| Jun 30, 2023 | -176.60 Mn |
| Mar 31, 2023 | -113.40 Mn |
| Dec 31, 2022 | 148.10 Mn |
| Sep 30, 2022 | -182.30 Mn |
| Jun 30, 2022 | -229.40 Mn |
| Mar 31, 2022 | -12.30 Mn |
| Dec 31, 2021 | -41.90 Mn |
| Sep 30, 2021 | 68.20 Mn |
| Jun 30, 2021 | -237.90 Mn |
| Mar 31, 2021 | 57.00 Mn |
| Dec 31, 2020 | 212.19 Mn |
| Sep 30, 2020 | 56.15 Mn |
| Jun 30, 2020 | -27.74 Mn |
| Mar 31, 2020 | 36.71 Mn |
| Dec 31, 2019 | 73.23 Mn |
| Sep 30, 2019 | 6.82 Mn |
| Jun 30, 2019 | 43.93 Mn |
| Mar 31, 2019 | 43.43 Mn |
| Dec 31, 2018 | -1.52 Bn |
| Sep 30, 2018 | 79,000.00 |
| Jun 30, 2018 | -71,000.00 |
| Mar 31, 2018 | 3.59 Mn |
| Dec 31, 2017 | -6.54 Mn |
| Sep 30, 2017 | -118.60 Mn |
| Jun 30, 2017 | 3.41 Mn |
| Mar 31, 2017 | 1.21 Mn |
| Dec 31, 2016 | -6.58 Mn |
| Sep 30, 2016 | 686,000.00 |
| Jun 30, 2016 | 20.80 Mn |
| Mar 31, 2016 | 2.06 Mn |
| Dec 31, 2015 | -4.51 Mn |
| Sep 30, 2015 | 1.45 Mn |
| Jun 30, 2015 | 6.35 Mn |
| Dec 31, 2014 | 281,000.00 |
| Dec 31, 2013 | -154.89 Mn |
| Sep 30, 2013 | 497,000.00 |
| Jun 30, 2013 | -1.96 Mn |
| Mar 31, 2013 | -128.70 Mn |
| Dec 31, 2012 | 901,000.00 |
| Sep 30, 2012 | 16.45 Mn |
| Jun 30, 2012 | 21.59 Mn |
| Mar 31, 2012 | -2.28 Mn |
| Dec 31, 2011 | 10.74 Mn |
| Sep 30, 2011 | -27.57 Mn |